Nicozid (Isoniazid)

Isoniazid, the active ingredient in Nicozid, is an antitubercular agent presented as an intravenous solution for intravenous use. It inhibits the synthesis of mycolic acids, essential components of the mycobacterial cell wall, and is employed in the treatment of active tuberculosis in adults and children as part of multidrug regimens.

GNH USA supplies Nicozid as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, and clinical centres worldwide. The company adheres to EU quality standards and provides regulatory documentation to support safe import and clinical use across multiple markets.

Isoniazid is used in the management of mycobacterial infections, primarily tuberculosis, across various disease presentations.

Tuberculosis: Integrated into standard multidrug regimens to kill actively replicating Mycobacterium tuberculosis, reduce bacterial load, and prevent resistance development. Latent TB infection: Administered as a prophylactic course to eradicate dormant bacilli, thereby lowering the risk of future active disease in individuals with recent exposure or immunocompromise. Extrapulmonary tuberculosis: Used in combination therapy for TB affecting lymph nodes, bones, or meninges, contributing to systemic bacterial clearance.

Isoniazid may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea and vomiting - Peripheral neuropathy (tingling or numbness) - Elevated liver enzymes (transaminases) - Rash or mild skin eruptions - Fever or chills

Serious or Rare Side Effects: - Hepatotoxicity, including hepatitis and liver failure - Severe hypersensitivity reactions such as Stevens‑Johnson syndrome - Aplastic anemia or other bone‑marrow suppression - Drug‑induced lupus erythematosus - Seizures, especially in overdose or with metabolic disturbances

When using Nicozid, clinicians should observe several safety measures. - Liver function monitoring: Baseline and periodic assessment of hepatic enzymes is recommended. - Peripheral neuropathy risk: Co‑administration of pyridoxine (vitamin B6) is advised to reduce neuropathy. - Alcohol consumption: Limit intake as concurrent alcohol may increase hepatotoxic risk. - Pregnancy and lactation: Use only if benefits outweigh potential risks; consult a specialist. - Drug interactions: Review concomitant medications for potential interactions. - Store at 2-8°C: Keep refrigerated, protect from light, do not freeze.

Isoniazid interacts with several medicines; some require avoidance while others need close monitoring.

Major Interactions (Avoid): - Rifampicin: Reduces isoniazid plasma levels, compromising efficacy. - Phenytoin: Increases hepatic metabolism, lowering isoniazid concentrations. - Alcohol: Potentiates hepatotoxicity.

Moderate Interactions (Monitor Closely): - Acetylhydrazine: May increase risk of liver injury. - Carbamazepine: May affect isoniazid metabolism. - Nevirapine: Potential additive hepatic toxicity.